NA NanoRepro AG Stock: price and insider trades · Germany · BaFinSource id BAFIN:nanorepro-ag ISIN ISIN DE0006577109DE · BaFin Mcap €22.3M 医疗与制药 Track the NanoRepro AG share price and the full directors' dealings record of the company, a listed equity based in Germany. Shares are quoted on the DE market, under the authority of BaFin. Operating in the Healthcare & Pharma sector, NanoRepro AG has published 15 reports. Market capitalisation: €22.3m. The latest transaction was filed on 18 August 2026 (Buy). Among the most active insiders: Stiller, Dr. Olaf. Every trade is free.
Fundamental score
Ranked 17,436 of 29,064 companies
FCF yld 42%
Earn yld -9.2%
EV/EBITDA ·
ROE -5.3%
Gross mgn 63%
Net mgn -44%
Debt/EBITDA ·
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 August 2026
All Executives15 Thresholds0 Prospectus0 Other0
Declarations 15 total
● Supervisory board · Executives · 17 Aug 2026
2,688.172 shares @ €1.86 0.021% mcap 6.2% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-f426a8007d4f ● Supervisory board · Executives · 31 Jul 2026
5,261.579 shares @ €1.90 0.042% mcap 13.2% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-8c6eeea0c4af ● Management Board · Executives · 29 May 2026
5,434.783 shares @ €1.84 0.041% mcap 17.5% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-25747d80e189 ● Supervisory board · Executives · 28 May 2026
30 shares @ €1.73 0.0002% mcap 0.1% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-039c2b31aff5 ● Management Board · Executives · 29 May 2026
6,983.641 shares @ €1.84 0.053% mcap 27.3% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-a8f95c647da8 ● Management Board · Executives · 27 May 2026
1,565.279 shares @ €1.79 0.011% mcap 8.2% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-8cdab42a3773 ● Supervisory board · Executives · 28 May 2026
10,000 shares @ €1.75 0.072% mcap 23.1% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-8847603b3e3a ● Management Board · Executives · 27 May 2026
5,570.874 shares @ €1.75 0.040% mcap 28.5% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-bfb6e96c25db ● Supervisory board · Executives · 26 May 2026
5,965.031 shares @ €1.63 0.040% mcap 16.7% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-42fbba4a4565 ● Supervisory board · Executives · 22 May 2026
1,750.617 shares @ €1.62 0.012% mcap 4.9% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-d93c9ec726dd ● Supervisory board · Executives · 19 May 2026
6,369.427 shares @ €1.57 0.041% mcap 17.2% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-c61cad71e889 ● Supervisory board · Executives · 19 May 2026
6,289.308 shares @ €1.59 0.041% mcap 17.2% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-78add94750d0 ● Management Board · Executives · 4 Aug 2025
5,010.886 shares @ €1.58 36.5% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-903602c6404d ● Management Board · Executives · 31 Jul 2025
8,494.34 shares @ €1.62 63.5% of flow Share ISIN ISIN DE0006577109BAFIN:40009328-79567ed7ab47 ● Supervisory board · Executives · 16 May 2025
20,078.125 shares @ €1.28 33.9% of flow Share ISIN ISIN DE0006577109BAFIN:40009328 关于 NanoRepro AG NanoRepro AG 是一家在Xetra/法兰克福（DAX/MDAX/SDAX）上市的德国公司，总部位于德国黑森州马尔堡。自2008年10月上市以来，该集团一直专注于开发、制造和分销用于家庭和专业用途的快速诊断自检产品，以及膳食补充剂。其核心定位是预防性医疗保健和自我诊断，这个市场受到日益增长的健康意识、消费者对便捷居家检测的需求以及通过药店、零售和在线渠道进行多渠道分销的推动。（[nanorepro.com](https://www.nanorepro.com/en/company?utm_source=openai))
从商业模式的角度来看，NanoRepro围绕“ZuhauseTEST”品牌和一系列CE认证产品建立了其特许经营权，涵盖生育、怀孕、胃部健康、不耐受、过敏、预防性筛查和传染病等领域。该公司强调产品灵活性、即时生产和持续的成本优化，这些对于在快速变化的消费者健康环境中运营的利基诊断公司来说是重要的优势。除了诊断产品，NanoRepro自2015年以来还以ALPHABIOL品牌提供膳食补充剂，使其能够在相邻的健康和保健类别中进行交叉销售。（[nanorepro.com](https://www.nanorepro.com/unternehmen?utm_source=openai))
在竞争方面，NanoRepro最好被视为一家专注的小盘股专业公司，而非一家完全整合的大型医疗保健集团。其优势在于速度、有针对性的产品发布以及诊断与消费者健康产品的结合。该公司服务于国内和国际市场，尽管德国仍然是其主要市场和运营基地。最近的披露还表明其零售业务不断增长，包括与主要的德国药店合作伙伴建立合作关系，这有助于扩大品牌知名度和分销范围。（[nanorepro.com](https://www.nanorepro.com/en/company?utm_source=openai))
最近的发展对投资者尤其重要。在COVID检测带来的意外之财消退后，NanoRepro报告称其基础业务在2024年明显复苏，核心收入（不包括COVID相关收入）增长约76%，总收入达到约4.4 million欧元。随后2024/2025财年的半年和全年更新显示，自检产品和补充剂业务持续保持增长势头，而盈利能力仍在转型中。与此同时，该公司通过持有Paedi Protect AG的多数股权以及2025年对hyped about science GmbH的投资（与冷等离子技术和PHLAS消费设备相关），拓宽了其战略选择。对于国际股票投资者而言，NanoRepro结合了医疗保健领域的敞口、资产负债表驱动的谨慎态度以及仍在建设中的多元化战略。（[nanorepro.com](https://www.nanorepro.com/presse-news/pressemitteilungen-de/nanorepro-veroeffentlicht-halbjahreszahlen-2024-umsatz-im-kerngeschaeft-steigt-investitionen-in-markenbekanntheit-zahlen-sich-aus?utm_source=openai))